Advisors Approve NCI Plan To Contract For Early Clinical Trials Of Imaging Agents.
NCI Recruits Carl Barrett Of NIEHS To Direct Basic Sciences; Freedman named to NCAB.
Sieber Direct Communications At NCI, Reorganizing Offices.
“5 A Day” Review Underway to Check Program’s Health at NCI.
AACR Honors Nine Cancer Researchers, Clinicians.
Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.
FDA Grants Six-Month Priority Review To Nolvadex For DCIS Adjuvant Treatment.
Bristol-Myers, Karolinska In Collaboration For Studies.
Antigenics Begins Phase II Trial Of Oncophage for NHL.
Aphton To Test Anti-Gastrin Drug At M. D. Anderson. NAS
RFP: Intellectual Property.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
